SyntekaBio Inc (226330) - Net Assets
Based on the latest financial reports, SyntekaBio Inc (226330) has net assets worth ₩28.34 Billion KRW (≈ $19.20 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩43.69 Billion ≈ $29.61 Million USD) and total liabilities (₩15.35 Billion ≈ $10.40 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 226330 capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩28.34 Billion |
| % of Total Assets | 64.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | 15.03% |
| 10-Year Change | N/A |
| Growth Volatility | 949.37 |
SyntekaBio Inc - Net Assets Trend (2017–2025)
This chart illustrates how SyntekaBio Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 226330 company net worth.
Annual Net Assets for SyntekaBio Inc (2017–2025)
The table below shows the annual net assets of SyntekaBio Inc from 2017 to 2025. Also explore SyntekaBio Inc net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩31.78 Billion ≈ $21.54 Million |
+27.41% |
| 2024-12-31 | ₩24.94 Billion ≈ $16.90 Million |
-20.13% |
| 2023-12-31 | ₩31.23 Billion ≈ $21.16 Million |
-0.74% |
| 2022-12-31 | ₩31.46 Billion ≈ $21.32 Million |
+13.88% |
| 2021-12-31 | ₩27.63 Billion ≈ $18.72 Million |
-33.49% |
| 2020-12-31 | ₩41.54 Billion ≈ $28.15 Million |
-9.91% |
| 2019-12-31 | ₩46.11 Billion ≈ $31.25 Million |
+2708.68% |
| 2018-12-31 | ₩1.64 Billion ≈ $1.11 Million |
+158.83% |
| 2017-12-31 | ₩-2.79 Billion ≈ $-1.89 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SyntekaBio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8156474659000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩125.61 Billion | 395.27% |
| Total Equity | ₩31.78 Billion | 100.00% |
SyntekaBio Inc Competitors by Market Cap
The table below lists competitors of SyntekaBio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ENERSIDE ENERGY EO -01
F:9O8
|
$18.74 Million |
|
Booster Co. Ltd
KQ:008470
|
$18.75 Million |
|
Advanced Connection Corporation Public Company Limited
BK:ACC
|
$18.75 Million |
|
Assura PLC
LSE:AGR
|
$18.77 Million |
|
Oxford Instruments PLC
LSE:OXIG
|
$18.73 Million |
|
Hawthorn Resources Ltd
AU:HAW
|
$18.73 Million |
|
111 Inc
NASDAQ:YI
|
$18.71 Million |
|
Allarity Therapeutics Inc
NASDAQ:ALLR
|
$18.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SyntekaBio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 24,943,253,090 to 31,779,056,310, a change of 6,835,803,220 (27.4%).
- Net loss of 17,378,023,880 reduced equity.
- New share issuances of 23,765,322,120 increased equity.
- Other factors increased equity by 448,504,980.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-17.38 Billion | -54.68% |
| Share Issuances | ₩23.77 Billion | +74.78% |
| Other Changes | ₩448.50 Million | +1.41% |
| Total Change | ₩- | 27.41% |
Book Value vs Market Value Analysis
This analysis compares SyntekaBio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.87x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩-242.53 | ₩1140.00 | x |
| 2018-12-31 | ₩142.67 | ₩1140.00 | x |
| 2019-12-31 | ₩3505.21 | ₩1140.00 | x |
| 2020-12-31 | ₩3108.82 | ₩1140.00 | x |
| 2021-12-31 | ₩2046.45 | ₩1140.00 | x |
| 2022-12-31 | ₩2327.37 | ₩1140.00 | x |
| 2023-12-31 | ₩2050.38 | ₩1140.00 | x |
| 2024-12-31 | ₩1634.71 | ₩1140.00 | x |
| 2025-12-31 | ₩1310.02 | ₩1140.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SyntekaBio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -54.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -506.76%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.46x
- Recent ROE (-54.68%) is below the historical average (-2.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -13302.49% | 0.02x | 0.00x | ₩-5.51 Billion |
| 2018 | 228.21% | 1307.34% | 0.02x | 7.38x | ₩3.58 Billion |
| 2019 | -49.81% | -4977.80% | 0.01x | 1.04x | ₩-27.58 Billion |
| 2020 | -15.62% | -1064.13% | 0.01x | 1.08x | ₩-10.64 Billion |
| 2021 | -53.58% | -4674.69% | 0.00x | 2.46x | ₩-17.57 Billion |
| 2022 | -14.32% | -1846.96% | 0.00x | 1.77x | ₩-7.65 Billion |
| 2023 | -36.50% | -9235.91% | 0.00x | 1.69x | ₩-14.52 Billion |
| 2024 | -28.92% | -5966.88% | 0.00x | 1.75x | ₩-9.71 Billion |
| 2025 | -54.68% | -506.76% | 0.07x | 1.46x | ₩-20.56 Billion |
Industry Comparison
This section compares SyntekaBio Inc's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $44,281,707,442
- Average return on equity (ROE) among peers: -18.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SyntekaBio Inc (226330) | ₩28.34 Billion | 0.00% | 0.54x | $18.74 Million |
| BIT Computer Co. Ltd (032850) | $31.24 Billion | 8.55% | 0.74x | $43.61 Million |
| ezCaretech Co. LTD (099750) | $46.10 Billion | 8.46% | 0.25x | $64.47 Million |
| Carelabs Co.Ltd (263700) | $68.53 Billion | -35.71% | 1.37x | $26.36 Million |
| LifeSemantics Corp. (347700) | $31.25 Billion | -56.00% | 0.43x | $769.52 Million |
About SyntekaBio Inc
SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, di… Read more